Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lantheus Holdings
(NQ:
LNTH
)
107.78
+1.22 (+1.15%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lantheus Holdings
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Cramer Calls Datadog 'Dynamite,' Puts SoFi In Dog House: 'What The Heck Is Going On'
March 19, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Marvell Technology, Inc. (NASDAQ: MRVL) reported a mixed quarter.
Via
Benzinga
The 7 Most Undervalued Mid-Cap Stocks to Buy in March 2024
March 13, 2024
Wager on these top undervalued mid-cap stocks, effectively blending growth and value, with a remarkable broader-market performance in 2023.
Via
InvestorPlace
Investors should take note of NASDAQ:LNTH, a growth stock that remains attractively priced.
March 08, 2024
Investors seeking growth at a reasonable cost should explore NASDAQ:LNTH.
Via
Chartmill
Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024
March 05, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
NASDAQ:LNTH—A High-Growth Stock Gearing Up for Its Next Upward Move.
March 05, 2024
LANTHEUS HOLDINGS INC (NASDAQ:LNTH), a strong growth stock, setting up for a breakout.
Via
Chartmill
Assessing Lantheus Holdings: Insights From 4 Financial Analysts
February 23, 2024
Via
Benzinga
Is NASDAQ:LNTH on the Verge of a Major Breakout as a Strong Growth Stock?
February 08, 2024
Why LANTHEUS HOLDINGS INC (NASDAQ:LNTH) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via
Chartmill
Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patients
March 04, 2024
DEFINITY is the #1 utilized ultrasound enhancing agent in the U.S. for patients with suboptimal echocardiograms
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer
February 28, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
NASDAQ:LNTH is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
February 28, 2024
LANTHEUS HOLDINGS INC (NASDAQ:LNTH) appears to be flying under the radar despite its strong fundamentals.
Via
Chartmill
NASDAQ:LNTH is showing good growth, while it is not too expensive.
January 26, 2024
For those who appreciate growth without the sticker shock, NASDAQ:LNTH is worth considering.
Via
Chartmill
Deep Dive Into Lantheus Holdings Stock: Analyst Perspectives (4 Ratings)
January 10, 2024
Via
Benzinga
Despite its impressive fundamentals, NASDAQ:LNTH remains undervalued.
December 25, 2023
LANTHEUS HOLDINGS INC (NASDAQ:LNTH) is an undervalued gem with solid fundamentals.
Via
Chartmill
Why Etsy Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
February 22, 2024
Shares of Etsy, Inc.
Via
Benzinga
NICE Posts Upbeat Earnings, Joins FTI Consulting, NVIDIA, Moderna And Other Big Stocks Moving Higher On Thursday
February 22, 2024
U.S. stocks were higher, with the Nasdaq Composite gaining more 2% on Thursday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results
February 22, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
NASDAQ:LNTH stands out as a growth opportunity that won't break the bank.
February 16, 2024
While growth is established for LANTHEUS HOLDINGS INC (NASDAQ:LNTH), the stock's valuation remains reasonable.
Via
Chartmill
Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
February 13, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8:00 a.m. Eastern Time
February 08, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Earnings Scheduled For February 22, 2024
February 22, 2024
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million.
Via
Benzinga
For those who appreciate value investing, NASDAQ:LNTH is a compelling option with its solid fundamentals.
February 05, 2024
LANTHEUS HOLDINGS INC (NASDAQ:LNTH): good value for what you're paying.
Via
Chartmill
Lantheus Announces CEO Succession Plan
January 23, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
For those who appreciate value investing, NASDAQ:LNTH is a compelling option with its solid fundamentals.
January 15, 2024
Don't overlook LANTHEUS HOLDINGS INC (NASDAQ:LNTH)—it's a hidden gem with strong fundamentals and an attractive price tag.
Via
Chartmill
Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate)
January 11, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics
January 09, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Reports Preliminary Fiscal Year 2023 Revenue
January 09, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
For those who appreciate growth without the sticker shock, NASDAQ:LNTH is worth considering.
January 05, 2024
Investors should take note of NASDAQ:LNTH, a growth stock that remains attractively priced.
Via
Chartmill
Lantheus to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
New Year, New Gains: The 3 Best AI Stocks to Buy in 2024
January 01, 2024
These AI stocks offer substantial upside potential compared to the overextended chip players that dominated the theme in 2023.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Lantheus Downgraded Due To Reliance On PNT2002; Analyst Cites Comparable Profile To Novartis' Drug
December 19, 2023
Monday, Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Phase 3 SPLASH trial of 177Lu-PNT2002 in metastatic c
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.